Literature DB >> 20061411

Galactoxylomannans from Cryptococcus neoformans varieties neoformans and grubii are structurally and antigenically variable.

Magdia De Jesus1, Siu-Kei Chow, Radames J B Cordero, Susana Frases, Arturo Casadevall.   

Abstract

Prior studies have established that the Cryptococcus neoformans capsular polysaccharide component galactoxylomannan (GalXM) manifests serotype-related structural differences that translate into antigenic differences. We analyzed GalXM from acapsular serotype A and D strains by carbohydrate analysis and static and dynamic light scattering to determine mass, effective diameter, polydispersity, and diffusion coefficients. Multiangle laser light scattering showed that GalXM from C. neoformans var. grubii strain cap59 (serotype A) had larger molecular mass (4.21 x 10(6) +/- 0.95 x 10(6) g/mol) and radius of gyration (207 +/- 27 nm) than GalXM from C. neoformans var. neoformans cap67 (serotype D). cap67 GalXM had corresponding values of 0.70 x 10(6) +/- 0.05 x 10(6) g/mol and 120 +/- 22 nm, respectively. The effective diameter for GalXM and polydispersity from the two strains varied depending on temperature and medium growth conditions, indicating that GalXM structure can vary within a strain, depending on its environment. Zeta potential determinations were negative for GalXM from both strains under all conditions, consistent with the recently reported presence of glucuronic acid. These results imply that C. neoformans GalXM, like glucuronoxylomannan, can manifest variety- and growth condition-related variations. Analysis of 16 C. neoformans and 7 Cryptococcus gattii strains with polyclonal antibody to a GalXM strain revealed antigenic similarities among the C. neoformans variety neoformans and grubii strains and no reactivity with C. gattii. As a result of the deleterious effects of GalXM on immune function, structural and antigenic variability between serotypes may translate into differences in immunomodulatory effects.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20061411      PMCID: PMC2901672          DOI: 10.1128/EC.00268-09

Source DB:  PubMed          Journal:  Eukaryot Cell        ISSN: 1535-9786


  29 in total

Review 1.  A yeast under cover: the capsule of Cryptococcus neoformans.

Authors:  Indrani Bose; Amy J Reese; Jeramia J Ory; Guilhem Janbon; Tamara L Doering
Journal:  Eukaryot Cell       Date:  2003-08

2.  Cell-wall glucans of Cryptococcus neoformans Cap 67.

Authors:  P G James; R Cherniak; R G Jones; C A Stortz; E Reiss
Journal:  Carbohydr Res       Date:  1990-04-02       Impact factor: 2.104

3.  Prevalence of Cryptococcus neoformans var. neoformans (Serotype D) and Cryptococcus neoformans var. grubii (Serotype A) isolates in New York City.

Authors:  J N Steenbergen; A Casadevall
Journal:  J Clin Microbiol       Date:  2000-05       Impact factor: 5.948

Review 4.  Cryptococcosis in the era of AIDS--100 years after the discovery of Cryptococcus neoformans.

Authors:  T G Mitchell; J R Perfect
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

5.  Galactoxylomannans of Cryptococcus neoformans.

Authors:  P G James; R Cherniak
Journal:  Infect Immun       Date:  1992-03       Impact factor: 3.441

6.  Cryptococcus neoformans CAP59 (or Cap59p) is involved in the extracellular trafficking of capsular glucuronoxylomannan.

Authors:  Javier García-Rivera; Yun C Chang; K J Kwon-Chung; Arturo Casadevall
Journal:  Eukaryot Cell       Date:  2004-04

Review 7.  Polysaccharide antigens of the capsule of Cryptococcus neoformans.

Authors:  R Cherniak; J B Sundstrom
Journal:  Infect Immun       Date:  1994-05       Impact factor: 3.441

8.  Galactoxylomannan-mediated immunological paralysis results from specific B cell depletion in the context of widespread immune system damage.

Authors:  Magdia De Jesus; André Moraes Nicola; Susana Frases; Ian R Lee; Steven Mieses; Arturo Casadevall
Journal:  J Immunol       Date:  2009-08-14       Impact factor: 5.422

9.  Complementation of a capsule-deficient mutation of Cryptococcus neoformans restores its virulence.

Authors:  Y C Chang; K J Kwon-Chung
Journal:  Mol Cell Biol       Date:  1994-07       Impact factor: 4.272

10.  Molecular characterization of the humoral responses to Cryptococcus neoformans infection and glucuronoxylomannan-tetanus toxoid conjugate immunization.

Authors:  J Mukherjee; A Casadevall; M D Scharff
Journal:  J Exp Med       Date:  1993-04-01       Impact factor: 14.307

View more
  16 in total

Review 1.  Emerging themes in cryptococcal capsule synthesis.

Authors:  Pardeep Kumar; Meng Yang; Brian C Haynes; Michael L Skowyra; Tamara L Doering
Journal:  Curr Opin Struct Biol       Date:  2011-09-01       Impact factor: 6.809

2.  Evidence for branching in cryptococcal capsular polysaccharides and consequences on its biological activity.

Authors:  Radames J B Cordero; Susana Frases; Allan J Guimaräes; Johanna Rivera; Arturo Casadevall
Journal:  Mol Microbiol       Date:  2011-01-05       Impact factor: 3.501

3.  Evaluation of Cryptococcus neoformans galactoxylomannan-protein conjugate as vaccine candidate against murine cryptococcosis.

Authors:  Siu-Kei Chow; Arturo Casadevall
Journal:  Vaccine       Date:  2011-01-14       Impact factor: 3.641

4.  Immunomodulatory effects of serotype B glucuronoxylomannan from Cryptococcus gattii correlate with polysaccharide diameter.

Authors:  Fernanda L Fonseca; Lilian L Nohara; Radames J B Cordero; Susana Frases; Arturo Casadevall; Igor C Almeida; Leonardo Nimrichter; Marcio L Rodrigues
Journal:  Infect Immun       Date:  2010-06-14       Impact factor: 3.441

5.  Glucuronoxylomannan, galactoxylomannan, and mannoprotein occupy spatially separate and discrete regions in the capsule of Cryptococcus neoformans.

Authors:  Magdia De Jesus; André Moraes Nicola; Siu-Kei Chow; Ian R Lee; Shuhua Nong; Charles A Specht; Stuart M Levitz; Arturo Casadevall
Journal:  Virulence       Date:  2010-11-01       Impact factor: 5.882

6.  Chronological aging is associated with biophysical and chemical changes in the capsule of Cryptococcus neoformans.

Authors:  Radames J B Cordero; Bruno Pontes; Allan J Guimarães; Luis R Martinez; Johanna Rivera; Bettina C Fries; Leonardo Nimrichter; Marcio L Rodrigues; Nathan B Viana; Arturo Casadevall
Journal:  Infect Immun       Date:  2011-10-03       Impact factor: 3.441

7.  Pbx proteins in Cryptococcus neoformans cell wall remodeling and capsule assembly.

Authors:  Pardeep Kumar; Christian Heiss; Felipe H Santiago-Tirado; Ian Black; Parastoo Azadi; Tamara L Doering
Journal:  Eukaryot Cell       Date:  2014-02-28

8.  Role of CD45 signaling pathway in galactoxylomannan-induced T cell damage.

Authors:  Eva Pericolini; Elena Gabrielli; Giovanni Bistoni; Elio Cenci; Stefano Perito; Siu-Kei Chow; Francesca Riuzzi; Rosario Donato; Arturo Casadevall; Anna Vecchiarelli
Journal:  PLoS One       Date:  2010-09-14       Impact factor: 3.240

9.  Disease-enhancing antibodies improve the efficacy of bacterial toxin-neutralizing antibodies.

Authors:  Siu-Kei Chow; Cameron Smith; Thomas MacCarthy; Mary Ann Pohl; Aviv Bergman; Arturo Casadevall
Journal:  Cell Host Microbe       Date:  2013-04-17       Impact factor: 21.023

10.  Unusual galactofuranose modification of a capsule polysaccharide in the pathogenic yeast Cryptococcus neoformans.

Authors:  Christian Heiss; Michael L Skowyra; Hong Liu; J Stacey Klutts; Zhirui Wang; Matthew Williams; Deepa Srikanta; Stephen M Beverley; Parastoo Azadi; Tamara L Doering
Journal:  J Biol Chem       Date:  2013-02-13       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.